This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Prognosis/ Outcomes  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Bryan A. Liang, MD, PhD, JD; Robert Lew, PhD; Justin A. Zivin, MD, PhD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

As Lansberg and Schwartz correctly point out, in the first of our analyses, based on Saver's article we included patients who recovered spontaneously and added the partial and complete recoveries to them, showing that more than half of the patients recovered to some extent when given the drug. However, we then provided an illustration based on the pooled data from all of the acute tPA stroke treatment trials available in the literature before our article was written (included in Figure 2 in the original article), which showed an improvement better than 50% and is not dependent on the article by Saver. Finally, our own independent analysis in the last example in the article (shown in the Table in the original article) using the Wilcoxon test indicated that 57.3% of the treated patients improved to . . . [Full Text of this Article]

AUTHOR INFORMATION



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Tissue Plasminogen Activator Does Not Benefit Most Eligible Patients With Stroke
Maarten G. Lansberg and Neil E. Schwartz
Arch Neurol. 2009;66(4):540-541.
EXTRACT | FULL TEXT